| Item Type | Name |
|
Concept
|
Administration, Topical
|
|
Concept
|
Administration, Rectal
|
|
Concept
|
Administration, Cutaneous
|
|
Concept
|
Administration, Intravesical
|
|
Concept
|
Administration, Oral
|
|
Concept
|
Drug Administration Routes
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Drug Administration Schedule
|
|
Academic Article
|
Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.
|
|
Academic Article
|
Treatment of detrusor instability with oxybutynin rectal suppositories.
|
|
Academic Article
|
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
|
|
Academic Article
|
Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide.
|
|
Academic Article
|
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
|
|
Academic Article
|
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
|
|
Academic Article
|
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
|
|
Academic Article
|
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
|
|
Academic Article
|
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
|
|
Academic Article
|
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
|
|
Academic Article
|
Transvaginal placement of surgical mesh for pelvic organ prolapse: more FDA concerns--positive reactions are possible.
|
|
Academic Article
|
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
|
|
Academic Article
|
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
|
|
Academic Article
|
The evolution of transdermal therapy for overactive bladder.
|
|
Academic Article
|
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
|
|
Academic Article
|
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
|
|
Academic Article
|
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
|
|
Academic Article
|
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
|
|
Academic Article
|
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
|
|
Academic Article
|
Transdermal delivery of drugs for urologic applications: basic principles and applications.
|
|
Academic Article
|
Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study.
|
|
Academic Article
|
Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis.
|
|
Academic Article
|
Evolving trends in the successful management of interstitial cystitis/painful bladder syndrome.
|
|
Academic Article
|
Oxybutynin: past, present, and future.
|
|
Academic Article
|
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
|
|
Academic Article
|
Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
|
|
Academic Article
|
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study.
|
|
Academic Article
|
A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS).
|